menu
    • menu
    [{"orgOrder":0,"company":"KM Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"KD-414","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KM Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"KM Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"KM Biologics \/ Not Applicable"},{"orgOrder":0,"company":"KM Biologics","sponsor":"Osivax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"OVX836","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"KM Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"KM Biologics \/ KM Biologics","highestDevelopmentStatusID":"14","companyTruncated":"KM Biologics \/ KM Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by KM Biologics

    Menu

    KM Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            KM Biologics

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            KM Biologics

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OVX836

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Osivax

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Osivax and KM Biologics Partner On Universal Flu Vaccine For Japan

                            Details : KM Biologics holds the exclusive license for the development, manufacturing, and commercialization of Osivax’s broad-spectrum OVX836 'universal' influenza vaccine candidates in Japan.

                            Brand Name : OVX836

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 10, 2024

                            Lead Product(s) : OVX836

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Osivax

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            KM Biologics

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            KM Biologics

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KD-414

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Japan's KM Biologics Begins Clinical Trial of COVID-19 Vaccine Candidate

                            Details : The first volunteer was injected with the inactivated virus vaccine known as KD-414, the company said in a release. The study is a combined Phase 1 and Phase 2 trial involving 210 subjects to test the vaccine’s safety and ability to trigger an immune r...

                            Brand Name : KD-414

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            March 22, 2021

                            Lead Product(s) : KD-414

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth